Arguments prove nothing unless verified. A commentary on Kaufman's "Epidemiologic analysis of racial/ethnic disparities: some fundamental issues and a cautionary example".
暂无分享,去创建一个
[1] J. Kaufman. Epidemiologic analysis of racial/ethnic disparities: some fundamental issues and a cautionary example. , 2008, Social science & medicine.
[2] Ralph D'Agostino,et al. Combination of isosorbide dinitrate and hydralazine in blacks with heart failure. , 2004, The New England journal of medicine.
[3] Clinical experience with perindopril in African-American hypertensive patients: a large United States community trial. , 2004, American journal of hypertension.
[4] Paul G Shekelle,et al. Efficacy of angiotensin-converting enzyme inhibitors and beta-blockers in the management of left ventricular systolic dysfunction according to race, gender, and diabetic status: a meta-analysis of major clinical trials. , 2003, Journal of the American College of Cardiology.
[5] D. DeMets,et al. Effect of Carvedilol on the Morbidity of Patients With Severe Chronic Heart Failure: Results of the Carvedilol Prospective Randomized Cumulative Survival (COPERNICUS) Study , 2002, Circulation.
[6] M. Drazner,et al. Efficacy of angiotensin-converting enzyme inhibition in reducing progression from asymptomatic left ventricular dysfunction to symptomatic heart failure in black and white patients. , 2002, Journal of the American College of Cardiology.
[7] A. P. Dawid,et al. Commentary: Counterfactuals: help or hindrance? , 2002 .
[8] S. Greenland,et al. Estimating causal effects. , 2002, International journal of epidemiology.
[9] A. Dawid. Counterfactuals: help or hindrance? , 2002, International journal of epidemiology.
[10] D. DeMets,et al. Effect of carvedilol on survival in severe chronic heart failure. , 2001, The New England journal of medicine.
[11] M. Domanski,et al. Lesser response to angiotensin-converting-enzyme inhibitor therapy in black as compared with white patients with left ventricular dysfunction. , 2001, The New England journal of medicine.
[12] J. DeSousa. Identification of patients most likely to benefit from implantable cardioverter-defibrillator therapy--the Canadian Implantable Defibrillator Study. , 2001 .
[13] A J Moss,et al. Implantable cardioverter defibrillator therapy: the sickest patients benefit the most. , 2000, Circulation.
[14] S. Saha. Racial differences in the outcome of left ventricular dysfunction. , 1999, The New England journal of medicine.
[15] B. Gersh,et al. Racial differences in the outcome of left ventricular dysfunction. , 1999, The New England journal of medicine.
[16] S. Yusuf,et al. Effect of enalapril on mortality and the development of heart failure in asymptomatic patients with reduced left ventricular ejection fractions. , 1992, The New England journal of medicine.
[17] S Greenland,et al. Matching and efficiency in cohort studies. , 1990, American journal of epidemiology.